HomeNewsBusinessCompaniesCOVID-19 impact | Wai Wai noodles to make up for the losses: Varun Chaudhary, Executive Director, CG Corp Global

COVID-19 impact | Wai Wai noodles to make up for the losses: Varun Chaudhary, Executive Director, CG Corp Global

Wai Wai enjoys close to 25 percent market share with some states having a share in excess of 60 percent.

May 15, 2020 / 20:34 IST
Story continues below Advertisement

Nepal-based CG Corp Global, maker of the popular Wai Wai noodles, is gearing up to make up for the losses owing to disruption in the supply chain on the back of COVID-19 lockdown. The company has set a sales target of Rs 1,000 crore for FY21, according to Varun Chaudhary, Executive Director, CG Corp Global.

"We will put every effort to ensure that we cover up for the losses that we have incurred, through the remainder year," Chaudhary told Moneycontrol in an interaction.

Story continues below Advertisement

Wai Wai entered the Indian instant noodles market in early 2003. In India, Wai Wai enjoys close to 25 percent market share with some states having a share in excess of 60 percent. Wai Wai, is also the second largest selling instant noodles brand in India.

Edited excerpts from the interview:

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show